Sangamo Therapeutics (SGMO) -
Event summary combining transcript, slides, and related documents.
Latest events from Sangamo Therapeutics
- Fabry and neurology advances, new partnerships, and $130M+ raised; funding needed for runway.SGMO
Q4 202530 Mar 2026 - Genentech deal and strong clinical results drive funding, but cash runway ends Q1 2025.SGMOQ2 20242 Feb 2026
- Genentech deal, Fabry fast track, and clinical wins drive Q3 profit, but funding risk persists.SGMOQ3 202414 Jan 2026
- Pipeline advances and partnerships drive progress, but urgent funding needed by mid-2025.SGMOQ4 202426 Dec 2025
- Up to $500M in securities offered, with $194.5M in common stock via Jefferies at-the-market.SGMORegistration Filing16 Dec 2025
- Board seeks approval for director elections, equity plan amendment, and auditor ratification.SGMOProxy Filing1 Dec 2025
- Fabry and Hemophilia A BLAs advance, with Nav1.7 gene therapy entering clinic in 2024.SGMOBarclays 27th Annual Global Healthcare Conference 202525 Nov 2025
- Fabry program advances, but urgent capital and partnership needs threaten operations past Q4 2025.SGMOQ2 202524 Nov 2025
- Lilly deal, pipeline progress, and cost cuts extend cash runway to late Q3 2025, but funding risks remain.SGMOQ1 202517 Nov 2025
- Net loss, revenue drop, and clinical advances highlight urgent need for new capital.SGMOQ3 202513 Nov 2025